Monopar Therapeutics Inc. (MNPR) Misses Q3 EPS by 27c

Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q3 EPS of ($0.37), $0.27 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.

You May Also Be Interested In

• UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue
• Corning (GLW) files for up to $2B offering of common shares